Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma
Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma
复制标题
DOI：
10.21873/anticanres.14804
复制
发表时间：
2021-01-01
影响因子：
2
通讯作者：
Takahashi, Shunji
中科院分区：
文献类型：
--
作者：
Sato, Yasuyoshi;Nakano, Kenji;Takahashi, Shunji
背景：淫羊藿素被广泛用于乳腺癌和软组织肉瘤的治疗。既往研究证实，治疗前淋巴细胞绝对计数、中性粒细胞/淋巴细胞比率(NLR)和C反应蛋白浓度可作为乳腺癌患者接受厄布林治疗的潜在预后指标。然而，埃布林治疗STS患者的预后因素尚未确定。患者和方法：这是2016年3月至2019年8月期间前瞻性收集的53名因复发或转移的STS而接受Eribuin治疗的患者的回顾分析。进行单变量和多变量分析以确定持久临床受益、无进展生存期和总生存期的预测因素。结果：L肉瘤组织学(危险比(HR)=28.20，95%可信区间(CI)=1.67-476.00；P=0.0211，治疗前NLR
Background: Eribulin is widely used for the treatment of breast cancer and soft-tissue sarcoma (STS). Previous studies identified the pre-treatment absolute lymphocyte count, baseline neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein concentration as potential prognostic markers in patients with breast cancer treated with eribulin. However, prognostic factors for eribulin treatment in patients with STS have not been identified. Patients and Methods: This was a retrospective analysis of data collected prospectively from 53 patients who were treated with eribulin for recurrent or metastatic STS between March 2016 and August 2019. Univariate and multivariate analyses were performed to determine the predictive factors of durable clinical benefit, progression-free survival, and overall survival. Results: L-Sarcoma histology (hazard ratio (HR)=28 20, 95% confidence interval (CI)=1.67-476.00; p=0.0211 and pre-treatment NLR